Articles tagged with Drug Studies
Researchers from the London School of Hygiene & Tropical Medicine found that intramuscular administration of tranexamic acid (TXA) is safe and quickly reaches therapeutic concentrations in pregnant women. Oral TXA was also well-tolerated but took an hour to reach therapeutic blood concentrations.
A recent clinical study found that an online e-health program helped more people with chronic pain reduce their opioid medications and pain intensity than a control group. The program, called Goalistics Chronic Pain Management, improved pain knowledge, confidence managing pain, and coping skills.
Researchers have shown lorlatinib to be safe and effective in treating high-risk neuroblastoma with ALK gene mutations. The targeted therapy has led to a major amendment in a phase 3 clinical trial, offering new hope for patients with this often lethal cancer.
Researchers found that using monoclonal antibodies within two days of a COVID-19 diagnosis reduced the risk of hospitalization or death by 39% compared to those who did not receive treatment. This finding suggests that early treatment with monoclonal antibodies significantly reduced the severity of COVID-19.
A multi-site NIH study shows that less than 1% of people with opioid use disorder experience withdrawal when starting buprenorphine in the emergency department. The findings provide strong evidence for safe and effective buprenorphine treatment, even for those using stronger opioids like fentanyl.
Researchers found that receipt of opioid use disorder-related telehealth services was associated with reduced risk for fatal drug overdoses. Additionally, medication from opioid treatment programs and buprenorphine in office-based settings also showed a protective effect.
A phase 3 randomised controlled trial found monthly injections of fitusiran effective in reducing bleeds in patients with severe haemophilia A or B. The study included 56 male patients with inhibitors, who experienced no bleeds after nine months on prophylactic treatment.
A new drug combination has doubled the expected time until cancer progression in heavily resistant head and neck cancer patients. The treatment, which includes a monoclonal antibody drug called ficlatuzumab, has shown an unusually high response rate of 38% in HPV-negative patients.
A global research team found that long-term methylphenidate treatment does not increase the risk of growth impairments or psychiatric events, but may lead to modest increases in blood pressure. The study suggests potential disparities in ADHD medication access by country-income levels.
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.
Receiving buprenorphine after a nonfatal opioid overdose significantly lowers the risk of subsequent overdose death. The medication was associated with a 62% reduction in risk, highlighting the need for lifesaving treatment following these events. Current evidence shows low uptake of buprenorphine and other medication-assisted treatments.
The Octapharma USA grant supports the Immunoglobulin National Society's breakfast symposium on PANS/PANDAS, a subset of pediatric acute-onset neuropsychiatric syndrome associated with strep. The program will focus on diagnosis criteria, pathogenic mechanisms, and current treatment options for challenging cases.
Corneal graft rejection can be as high as 10% due to poor patient compliance with medications, which require frequent eyedrop administrations. Researchers at Virginia Commonwealth University developed nanoparticles to encapsulate eye medication, decreasing graft rejection while requiring fewer and smaller doses. The approach reversed s...
Researchers at Tel Aviv University found that dedicated hyperbaric oxygen therapy is more effective in reducing pain and healing patients with fibromyalgia caused by traumatic brain injury. The treatment resulted in significant improvements in 2 out of 5 patients, including improved pain threshold tests and quality of life indicators.
A study found that people with epilepsy have a higher risk of early death, especially in younger individuals, those taking multiple medications, and those living in rural areas. The increased risk varies depending on the individual's specific circumstances.
The new medicine has shown promising results in a Phase 1 clinical trial, with 70% of patients stable after six weeks and one patient remaining stable for over two years. Developed by NTNU researcher Marit Otterlei, ATX-101 targets cancer cells' stress regulation system, leaving healthy cells unaffected.
A pilot study found that patients who listened to their favorite music experienced reduced nausea severity and distress. Music was believed to affect serotonin levels, a neurotransmitter associated with chemotherapy-induced nausea, in a way that could complement medication.
Researchers have discovered a novel medication that effectively treats a rare hereditary muscle disease causing complete immobility and death. The treatment has also shown promise in treating severe statin-associated myopathy, with improved symptoms in patients awaiting treatment.
Cases of Candida auris, a highly contagious fungal infection, rose drastically between 2019 and 2021, with an increase in echinocandin-resistant cases. The findings emphasize the need for improved detection and infection control practices to prevent the spread of C auris.
A new study reveals that the SPUR tool, developed by Kingston University and Observia, can accurately predict hospital admissions and early readmissions in people with Type 2 Diabetes. The tool has been found to be effective in reducing hospital admissions and improving patient outcomes.
Researchers at the Salk Institute discovered that combining two therapeutic drugs, entinostat and trametinib, can significantly reduce tumor volume and number in mice with LKB1-mutated non-small cell lung cancer. The findings could lead to clinical trials in humans and potentially transform treatment for cancers beyond NSCLC.
Experts advocate for genetic testing to identify MS patients at high risk of developing progressive multifocal leukoencephalopathy (PML), a devastating side effect from medications. The availability of such testing could allow physicians to use alternative therapies, reducing the risk of PML.
A new study published in the New England Journal of Medicine found that lebrikizumab was effective in treating moderate to severe atopic dermatitis, improving skin clarity and reducing itching. The study involved two phase 3 trials with over 700 participants and showed promising results for the treatment.
A multicenter study found that patients with cystic fibrosis can safely take a dual combination of CF modulator drugs for four years while maintaining previously achieved clinical improvement. This breakthrough therapy has improved the quality and length of patients' lives, with some even seeing a 15% increase in lung function.
A new study found that bupropion, an antidepressant medication, can help people stop using cocaine while receiving methadone for opioid use disorder. Participants who received monetary incentives to quit cocaine saw a higher success rate when taking bupropion compared to those with placebo.
A new study published in The Lancet found that an existing drug, sulfadoxine-pyrimethamine, protects pregnant women from sexually transmitted and reproductive tract infections. Researchers tested this drug alongside a promising new treatment, dihydroartemisinin-piperaquine, which showed unique ability to prevent malaria.
Researchers from China conducted a comprehensive review of dual therapy (DT) for H. pylori eradication, highlighting its high efficacy and patient compliance with minimal adverse events. High-dose DT administered over 14 days has emerged as the most effective treatment option.
A study by University of Georgia researchers found that revised prescription labels with explicit instructions can dramatically improve medication adherence to antihypertension medications, contraceptives, and asthma controllers. This improvement was seen in patients taking these medications, including those with asthma, hypertension, ...
Recent review article discusses clinical development in long-acting growth hormone (LAGH) therapy, which mimics natural GH release patterns. LAGH therapies reduce daily injection burden, improving patient compliance and treatment outcomes.
A phase two trial found that exenatide significantly reduced brain pressure and monthly headaches in seven patients with Idiopathic Intercranial Hypertension (IIH). The study showed a rapid action of the drug, with results indicating significant reductions in brain pressure and headache days compared to the placebo arm.
The magrolimab plus azacitidine regimen resulted in a complete response rate of 33% and partial response rate of 75%. Patients with TP53 mutations showed improved overall survival rates compared to previous studies.
Researchers at Brigham and Women's Hospital tested a new nasal monoclonal antibody treatment, Foralumab, which decreased inflammatory markers and lung inflammation in patients with COVID-19. The treatment also showed similar effects in multiple sclerosis patients, suggesting its potential use for treating other diseases.
A new study reveals that military members with mild traumatic brain injury (mTBI) who identify as 'Other' are at a significantly higher risk of suicide and overdose deaths. The study found that the rates of these deaths were highest among members of this group, despite making up only 7.38% of the study sample.
A new study published in Arthritis & Rheumatology reports significant improvements in disease activity for patients with refractory juvenile dermatomyositis treated with abatacept therapy. The randomized controlled trial demonstrates the potential of abatacept as a treatment option for this rare and debilitating condition.
A new drug called CADD522 blocks a gene associated with driving bone cancer's spread, increasing survival rates by 50% in mice implanted with human bone cancer. The breakthrough treatment shows promise in all main bone cancer subtypes and has the potential to save lives and reduce disability.
A new study by Weill Cornell Medicine found that the FDA's mandate to limit opioid-acetaminophen combinations resulted in significant reductions in liver injuries. The mandate, implemented in 2014, limited the dosage of acetaminophen in these drugs, leading to a decline in hospitalizations and acute liver failure cases.
A study found that a commercial water purifier may have caused Mycobacterium abscessus infections in 4 cardiac surgery patients due to chlorine depletion. The hospital's water system was contaminated via municipal water, emphasizing the importance of monitoring and preventing mycobacteria.
Two compounds, A5 and C1, have shown promising results in inhibiting the growth of glioblastoma cells, a type of aggressive brain cancer. Further research is needed to confirm their effectiveness on normal nerve cells and to move towards clinical trials.
The HALP score, a novel immune-nutritional marker, has been linked to prognostic ability in different cancer types. It integrates indicators of immune status and nutritional status, showing promise as a cost-effective biomarker.
A new cutaquig study found that increasing infusion volume per site resulted in a reduction of injection sites, while increasing infusion rates decreased infusion duration. The research also showed that dosing every other week demonstrated equivalency to trough levels with weekly dosing.
High-dose anticoagulation reduces intubations and deaths by 30% in hospitalized COVID-19 patients, especially those with ARDS. The study found a significant reduction in mortality and need for ICU care among patients treated with therapeutic anticoagulation.
A virtual care team consisting of physicians and pharmacists improved the adoption of life-saving therapies in patients with heart failure, leading to increased use of evidence-based treatments and better patient outcomes. The strategy was safe and effective, with comparable length of stay and safety events between the groups.
Researchers have discovered a gene mutation that can block chronic pain and provide protection against other stimuli, including heart and brain cells. The TRPV1 receptor mutation, found in avian species, was successfully transplanted into mice, showing reduced pain sensitivity and improved protective effects.
A new study found that walking an additional 500 steps per day was associated with a 14% lower risk of heart disease, stroke or heart failure. This benefit is significant for older adults, as most studies have focused on early-to-midlife adults.
Two studies found that adults with high cardiovascular health scores tend to live longer lives free of major chronic diseases. The research highlights the importance of maintaining ideal cardiovascular health to delay onset of age-related diseases, allowing individuals to enjoy life in their years as well as their years in life.
Researchers found that adding immunotherapy before surgical removal of stage III-IV melanoma significantly improved event-free survival compared to standard-of-care treatment. The study showed that neoadjuvant therapy is superior to the same therapy given in the adjuvant setting.
A clinical study by Indiana University School of Medicine researchers found that oral verapamil can improve pancreatic beta cell function in children with new-onset type 1 diabetes, with a 30% increase in insulin secretion over the first year. The trial involved 88 participants and was published in JAMA.
The CALYPSO study assesses the efficacy of combined MET and PD-L1 inhibition in patients with MET-driven metastatic papillary renal cancer. Response rates were 29% for all patients and 53% for those with MET-driven tumors, with improved progression-free survival observed in MET-driven status.
The BIAL Award in Biomedicine is a prestigious international award that recognises outstanding biomedical research. The €300,000 prize is given to researchers whose work has shown exceptional quality and scientific relevance, published within the last ten years.
A study found that over 80% of American adults with type 2 diabetes meet the criteria to use GLP-1 RAs or SGLT2is, but only a small percentage are using them. The medications have a substantially higher cost than current first-line treatments, making it difficult for patients to access them.
A preliminary study by the American Academy of Neurology found that Black people with dementia are receiving dementia-related medications less often than white people. The study revealed significant disparities in access to treatments, with Black patients receiving fewer prescription types compared to their white counterparts.
A University of Minnesota-led study shows that verapamil can increase pancreatic insulin secretion by 30% in children with newly-diagnosed type 1 diabetes. The treatment was well-tolerated and had a favorable safety profile, making it an appealing option for children and adults with the condition.
A recent study by the University of Kentucky Markey Cancer Center validates a new radiopharmaceutical compound as a viable treatment option for patients with advanced cervical cancer. The radioactive drug, 212Pb-DOTAM-GRPR1, targets gastrin-releasing peptide receptor, a protein expressed by cancer cells.
Researchers found that dose escalation to 600mg of ME improved disease control in five patients, while stable disease was observed in another five patients with an average duration of 15 weeks. Additionally, patients reported overall improved quality of life via a questionnaire.
A new clinical trial has shown safety and tolerability of oral GABA and reduced serum glucagon levels in children with recent onset Type 1 diabetes. The study focused on the potential of GABA and GAD to preserve insulin-secreting beta cells and attenuate excessive glucagon release.
Researchers from the University of Oxford-affiliated researchers found that high doses of ivermectin are ineffective in treating COVID-19. The study used the PLATCOV trial to compare the rates at which different drugs reduced the viral load of SARS-CoV-2, and the results suggest that ivermectin does not have measurable antiviral activity.
Researchers identified apremilast as an incredibly promising treatment for alcohol use disorder, reducing consumption by more than half in a clinical trial. The medication, approved for psoriasis and psoriatic arthritis, triggers increased activity in the brain's nucleus accumbens to control alcohol intake.
Researchers found that a combination of symptom and high-level viral rebound after untreated COVID-19 infection is rare, occurring in only 3 percent of study participants. This suggests that accounting for underlying rates of symptom relapse is crucial when evaluating antiviral treatment effects.
Researchers found that doxycycline postexposure prophylaxis did not prevent chlamydia or gonorrhea among cisgender women in a clinical trial. The lack of efficacy was attributed to differences in anatomy and antibiotic resistance.
A groundbreaking study found that a new TB treatment strategy can shorten treatment duration while maintaining effectiveness. The TRUNCATE-TB trial showed that an initial 8-week treatment period followed by retreatment for those not cured was as effective as the standard 6-month treatment but halved the average total time on treatment.